On November 13, 2020, based on the PFS results of KEYNOTE-355, the FDA accelerated the approval of pembrolizumab combined with chemotherapy (albumin paclitaxel/paclitaxel/gemcitabine + carboplatin) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1(CPS≥10), as determined by an FDA-approved test(Dako PD-L1 (22C3). The gene discussed is CD274; the disease is triple-negative breast carcinoma.